BioArmix
Biological Crop Protection Using Predatory Bacteria
Company Overview
Snapshot
Founded in February 2024 by Tzvi Zvirin, Gal Sason, Amos Nussinovitch, and Edouard Jurkevitch, BioArmix operates with 1–10 employees. The company has raised $23,000 across two funding rounds from one investor. In October 2025, BioArmix secured a grant from the EIT Food Accelerator Network.
Business overview
BioArmix develops biological solutions for sustainable agriculture and enhanced food security by combating bacterial plant pathogens. The company utilizes naturally occurring, non-GMO predatory bacteria that specifically target harmful gram-negative bacterial pathogens affecting crops. To ensure practical application and effectiveness, BioArmix employs a proprietary encapsulation technique that preserves the viability of the bacteria in a stable, dry powder form at room temperature. The company operates within the Agriculture & Food Technologies sector, focusing on Ag Tech, Genetics & Input, Climate Tech, Food & Land Use, and Sustainable Farming.
Strategic signal
In October 2024, BioArmix was featured in AgFunderNews for its novel approach to tackling bacterial pathogens with predatory biologicals. This highlights the company's innovative use of non-GMO predatory bacteria and proprietary encapsulation techniques, signaling a potential shift towards more sustainable and effective crop protection methods in the agricultural industry. For investors, this indicates strong market validation and a forward-looking strategy in the rapidly evolving agritech landscape.
Log in to access full profile ›Company Intelligence Q&A
- When was BioArmix founded?
- BioArmix was founded in February 2024 by Tzvi Zvirin, Gal Sason, Amos Nussinovitch, and Edouard Jurkevitch.
- What is BioArmix's primary focus?
- BioArmix focuses on developing biological solutions to combat bacterial plant pathogens, promoting sustainable agriculture and enhanced food security through the use of naturally occurring, non-GMO predatory bacteria.
- How does BioArmix ensure the stability of its biological solutions?
- BioArmix employs a proprietary encapsulation technique to preserve the viability of its predatory bacteria, allowing them to be stored in a dry powder form that remains stable at room temperature.